Clinical Trial Update: Bioequivalence Study of 300 mg Gabapentin [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the bioequivalence of 300 mg gabapentin formulations has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Drugs mentioned

• Gabapentin (Gabapentin)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Epilepsy | Phase 1 | Status: COMPLETED